Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

09 June 2022

For poorer countries, lack of access to antibiotics worsens resistance

In an article for CIDRAP News, Chris Dall reports about the Access to Medicine Foundation's latest study, titled "Lack of access to medicine is a major driver of drug resistance. How can pharma take action?"

Direct links

Read the article

"Access becomes so under-represented in our discussion about drug resistance that we forget that people are dying from preventable infections even though we have an arsenal of drugs today," the author writes, quoting Jayasree K. Iyer, CEO of the Access to Medicine Foundation. 

The article outlines the six case studies featured in the report, as well as its key findings, quoting Fatema Rafiqi, AMR Research Programme Manager at the Foundation: "It was very disturbing to see how few generic medicines actually had any access strategy associated with them. These medicines weren't getting into these low- and middle-income countries, where there was a very dire need."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved